CEVEC Pharma Signs License Agreement With Yuhan Corporation of South Korea
Published: Dec 20, 2012
CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.
“With Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We’re very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules. I’m convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases “ stated Wolfgang Kintzel, CEO at CEVEC.
Dr. Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: “After evaluating CAP and CAP-T we are excited about the potential of CEVEC’s CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it’s authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules"
About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.
Yuhan Corporation, the leading pharmaceutical company in South Korea, is focusing its R&D capabilities on new chemical entities, new biologics, herbal medicines, and APIs for global markets. For the last 86 years, Yuhan is committed to deliver advanced and innovative medicines with a slogan “Innovative, Nimble, and Translational R&D”. In 2007, ‘Revanex’, the world’s first acid pump agonist was out-licensing to China, and is now supplied world-wide to markets in Asia. Yuhan is to become the global premiere customer-focused pharma company with value driven, globally competitive R&D capability.
Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 – 00
fax +49 (0) 221-46 02 08 – 01
Jong-Gyun Kim, Ph.D.
Head, BioInnovation Unit, Yuhan Corporation
416-1 Gongse-dong, Yongin-si, Korea
Tel +82 31-899-4168
Fax +82 31-275-6145